Organigram Reports Q3 Financial Results – Increased Product Quality – 25% Patient Growth

SHARE THIS POST MONCTON, NEW BRUNSWICK–(Marketwired – July 28, 2017) – Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) (“Organigram” or the “Company“) announces the financial results for the quarter ending May 31, 2017. Organigram’s financial results for the quarter completed May 31, 2017 included expenses associated with the implementation of an industry leading quality assurance program (the “QA Program“). The QA Program was implemented to ensure that the Company produces the highest quality product available in the marketplace and in response to a previously announced voluntary recall of certain product produced in 2016. As a result of Organigram’s increased focus on product quality and safety with the stated objective of establishing a leadership position in such regard within the industry, the Company focused on introducing product of the highest quality to the market. In practice, the program effectively identified product lots that were to be removed from inventory well before being introduced to the marketplace. The successful implementation of this program resulted in a reduction in inventory value for the quarter. Organigram is pleased with the results and progress made during the quarter from an operational perspective and management is confident that these actions build the foundation for long-term success for the Company. This focus on product quality contributed to a 25% net increase in registered patients in Q3 when compared to Q2. Additionally, the Company continued to make significant headway...

Read More

ABcann Global Announces Inclusion on the Horizons Medical Marijuana Life Sciences ETF

SHARE THIS POST OTTAWA, July 05, 2017 (GLOBE NEWSWIRE) — ABcann Global Corporation (TSX-V:ABCN) (“ABcann” or the “Company“) is pleased to announce its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX:HMMJ) (the “ETF”). The ETF is the first of its kind and offers investors direct exposure to a basket of North American publicly listed life sciences companies with significant business activities in the medical marijuana sector. The ETF is an index (or passively managed) ETF, which seeks to replicate, to the extent possible, the performance of the North American Medical Marijuana Index (the “Index”), net of expenses....

Read More

Umbral ACMPR Applicant Phyeinmed Prepares To Expand Over 420,000 Square Feet

SHARE THIS POST Vancouver, B.C., July 6, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (“Umbral or Company”) and the management of PhyeinMed Inc. (“PhyeinMed”) a late stage applicant under the ACMPR (Access to Cannabis for Medical Purposes Regulations) are pleased to announce that planning and preparations have begun to build a 420,000 square foot cannabis production facility consisting of two buildings on 13 acres of land in Falkland, British Columbia. On May 26, 2017 Health Canada released a bulletin updating the application stages, increasing production based on vault size and providing applicants the opportunity to expand current application sites...

Read More

Umbral Enters Into Definitive Agreement To Acquire Additional 25% In Late Stage Applicant Phyeinmed And Provides Corporate Update

SHARE THIS POST Vancouver, B.C., July 5, 2017 – UMBRAL ENERGY CORP. (CSE: UMB) (the “Company” or “Umbral”) is pleased to announce that it has entered into a share purchase agreement dated effective June 21, 2017 (the “SPA”) among Umbral, its wholly-owned subsidiary 1005477 B.C. Ltd., Estek Ventures Corp. (the “Vendor”) and Debra Senger (“Senger”).Umbral and the Vendor currently each own 50% of the issued and outstanding common shares of PhyeinMed Inc. (PhyeinMed”), a late stage Health Canada Access to Cannabis for Medical Purposes Regulations (“ACMRP”) applicant for the purpose of growing, selling and distributing medical cannabis. Pursuant to...

Read More

Aphria Inks Major Wholesale Supply Agreement with Scientus Pharma, Health Canada Licensed Dealer

SHARE THIS POST Agreement to generate approximately $5 million in revenue for Aphria over 12-month contract LEAMINGTON, ONTARIO – July 4, 2017 – Aphria Inc. (“Aphria” or the “Company”) (TSX: APH or USOTCQB: APHQF), through its subsidiary Pure Natures Wellness Inc. (o/a Aphria), is pleased to announce that it entered into a major wholesale supply agreement with HydRx Farms, Ltd. (o/a Scientus Pharma) (“Scientus Pharma”). Under the terms of the Agreement, Aphria is committing to supply over 25,000 fully grown medical cannabis plants over the next 12 months to Scientus Pharma. The first delivery, under the agreement will occur in the middle of...

Read More

The Hydropothecary Corporation Announces Q3 2017 Results

SHARE THIS POST GATINEAU, QC–(Marketwired – June 29, 2017) – In the news release, “The Hydropothecary Corporation Announces Q3 2017 Results,” issued earlier today by The Hydropothecary Corporation (TSX VENTURE: THCX), we are advised by the company that the two rows below the table titled “Adjusted EBITDA” should be removed as they are incorrect. Complete corrected text follows. The Hydropothecary Corporation Announces Q3 2017 Results The Hydropothecary Corporation (TSX VENTURE: THCX) (“THCX” or the “Company”) today reported its third quarter results, for the three and nine months ended April 30, 2017. The Company’s financial statements and related management’s discussion...

Read More
  • 1
  • 2